Yes, you can start metformin in this patient with creatinine 1.26 mg/dL and eGFR 57 mL/min/1.73 m²
Metformin is safe to initiate at an eGFR of 57 mL/min/1.73 m² and is actually recommended as first-line therapy for patients with type 2 diabetes and chronic kidney disease when eGFR ≥30 mL/min/1.73 m² 1.
Dosing Strategy at eGFR 57 mL/min/1.73 m²
Since this patient's eGFR falls in the 45-59 mL/min/1.73 m² range, you have two options:
Standard dosing: Start with 500 mg or 850 mg once daily (immediate release) or 500 mg daily (extended release), then titrate upward by 500 mg/week or 850 mg every 2 weeks until maximum dose 1, 2
Consider dose reduction: For some patients in the 45-59 range who have comorbidities that increase lactic acidosis risk (heart failure, liver disease, chronic lung disease with hypoxemia), you may want to initiate at half the standard dose 1, 3
For most patients with eGFR 57 and no high-risk comorbidities, standard dosing is appropriate. The dose reduction is primarily recommended when eGFR falls below 45 mL/min/1.73 m² 1.
Monitoring Requirements
At this level of kidney function, you must:
- Monitor eGFR every 3-6 months (not just annually, since eGFR <60) 1, 3
- Continue same dose as long as eGFR remains 45-59 mL/min/1.73 m²
- Reduce dose to maximum 1000 mg daily if eGFR drops to 30-44 mL/min/1.73 m² 1, 3, 4
- Stop metformin if eGFR falls below 30 mL/min/1.73 m² 1, 2
Additional Considerations
Vitamin B12 monitoring: Plan to check vitamin B12 levels after 4 years of continuous metformin use 1.
Sick day rules: Educate the patient to temporarily stop metformin during acute illness, dehydration, or before procedures with iodinated contrast (especially important at eGFR <60) 2, 4.
Combination therapy: Current guidelines recommend adding an SGLT2 inhibitor to metformin for most patients with type 2 diabetes and CKD with eGFR ≥30 (now ≥20 for some agents), as this combination provides cardiovascular and kidney protection beyond glycemic control 1, 3.
Safety Profile
The concern about lactic acidosis with metformin in mild-moderate CKD has been largely dispelled by recent evidence. Multiple large studies show metformin is associated with reduced mortality at eGFR ≥45 mL/min/1.73 m² and no increased risk of acidosis until eGFR drops below 30 5, 6, 7. The FDA revised its labeling in 2016 to reflect this improved safety understanding, changing from a creatinine-based cutoff to the current eGFR-based approach 2.
Common pitfall: Don't confuse the initiation threshold with the continuation threshold. While you shouldn't start metformin if eGFR is 30-44 mL/min/1.73 m², you can continue it (at reduced dose) in patients already taking it whose eGFR declines to this range 1, 2.